Clinical trial
Recombinant Humanized Anti-CD52 Monoclonal Antibody in the Treatment of Relapsed and Refractory NHL and Initially Treated T-PLL Phase I Clinical Study on Safety and Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy
NCT05557903 is registered in ClinicalTrials.gov with Lanzhou Institute of Biological Products Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Recombinant Humanized Anti-CD52 Monoclonal Antibody in the Treatment of Relapsed and Refractory NHL and Initially Treated T-PLL Phase I Clinical Study on Safety and Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy
- Lead sponsor
- Lanzhou Institute of Biological Products Co., Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 20, 2021
- Completion date
- June 30, 2023
- Enrollment
- 71 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.